Tag Archives: tax inversion

AbbVie will buy Shire in another Pharma tax inversion strategy

Posted on July 18, 2014 by Alexander Szewczak

Following on the heels of Mylan, AbbVie will buy Shire in a move that, among other things, will result in a significantly lower tax rate when the redomiciled company is fully headquartered in Ireland. More information can be found here (WSJ) and here … Continue reading →

Posted in Economics, Pharmaceutical Industry | Tagged , , , , | 1 Comment

Generic drug maker Mylan pulls a mini-Pfizer tax inversion

Posted on July 15, 2014 by Alexander Szewczak

Taking a page from Pfizer’s playbook, Mylan is buying Abbott Laboratories’ branded specialty and generics businesses in developed markets outside the U.S..  The $5B deal is structured to result in a tax inversion, with the newly formed merged company to be headquartered in the Netherlands. “We see … Continue reading →

Posted in Pharmaceutical Industry | Tagged , , , | 1 Comment